T. Rowe Price Associates
ICVX

T. Rowe Price Associates’s Icosavax, Inc. Common Stock ICVX Stock Holding History

T. Rowe Price Associates’s Portfolio ICVX Stock Details ICVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,342,470
Closed -$19.2M – 3058
2022
Q2 		$19.2M Buy
3,342,470
+1,506,613
+82% +$11.8M ﹤0.01% 1179
2022
Q1 		$12.9M Buy
1,835,857
+237,305
+15% +$3.73M ﹤0.01% 1329
2021
Q4 		$36.6M Buy
1,598,552
+246,423
+18% +$6.36M ﹤0.01% 1109
2021
Q3 		$40M Buy
+1,352,129
New +$45.8M ﹤0.01% 1096

Other funds holding ICVX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates's ICVX Position: Q3 2022 in Review

T. Rowe Price Associates sold out of Icosavax, Inc. Common Stock (ICVX) in Q3 2022, closing a stake of 3,342,470 shares — an estimated $19.2M sold.

T. Rowe Price Associates first reported a position in ICVX in Q3 2021 and held it in 4 quarters. The position peaked at $40M in Q3 2021. 73 funds tracked by Wall St. Rank hold ICVX as of Q3 2022.

  • T. Rowe Price Associates reported no remaining Icosavax, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 3,342,470 Icosavax, Inc. Common Stock shares in Q3 2022, an estimated $19.2M.
  • T. Rowe Price Associates first reported a position in Icosavax, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • T. Rowe Price Associates's Icosavax, Inc. Common Stock position peaked at $40M in Q3 2021.
  • 73 funds tracked by Wall St. Rank held Icosavax, Inc. Common Stock as of Q3 2022.

Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.